no image available Dickens & Co. "Beating the Odds: Bevacizumab's Rise to the Fore in Elderly Patients with Metastatic Colorectal Cancer" "A Community-Based Study Uncovers the Surprising Benefits of Adding Bevacizumab to First-Line Treatment in Seniors with Advanced-Stage CRC" Price: 32.00€